AG2R LA Mondiale Gestion D Actifs Makes New $1.35 Million Investment in Insulet Corporation $PODD

Key Points

• AG2R LA Mondiale Gestion D Actifs made a new investment of approximately $1.35 million in Insulet Corporation by acquiring 4,293 shares in the second quarter.
• Insulet's Q2 earnings report showed a significant revenue increase of 32.9% year-over-year, with an EPS of $1.17, surpassing the consensus estimate of $0.92.
• Several hedge funds, including Vanguard Group Inc. and American Century Companies Inc., have recently increased their holdings in Insulet, reflecting growing institutional interest in the company.

AG2R LA Mondiale Gestion D Actifs acquired a new stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 4,293 shares of the medical instruments supplier's stock, valued at approximately $1,349,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Insulet by 2.1% during the first quarter. Vanguard Group Inc. now owns 8,668,952 shares of the medical instruments supplier's stock valued at $2,276,553,000 after acquiring an additional 178,976 shares during the period. American Century Companies Inc. grew its position in Insulet by 34.8% during the 1st quarter. American Century Companies Inc. now owns 1,152,606 shares of the medical instruments supplier's stock worth $302,686,000 after purchasing an additional 297,734 shares in the last quarter. Groupama Asset Managment raised its stake in Insulet by 0.4% during the 1st quarter. Groupama Asset Managment now owns 1,053,759 shares of the medical instruments supplier's stock valued at $276,728,000 after purchasing an additional 3,759 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Insulet by 4.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 674,367 shares of the medical instruments supplier's stock valued at $177,096,000 after purchasing an additional 27,408 shares in the last quarter. Finally, Federated Hermes Inc. boosted its position in shares of Insulet by 23.4% in the first quarter. Federated Hermes Inc. now owns 632,869 shares of the medical instruments supplier's stock worth $166,198,000 after buying an additional 120,197 shares during the period.

Insider Buying and Selling at Insulet

In related news, SVP Prem Singh sold 687 shares of the stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president owned 3,456 shares in the company, valued at $1,200,925.44. This represents a 16.58% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Laetitia Cousin sold 797 shares of the firm's stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the completion of the sale, the senior vice president directly owned 3,890 shares in the company, valued at $1,356,870.90. This trade represents a 17.00% decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.39% of the company's stock.

Insulet Stock Down 0.8%

Shares of PODD stock opened at $320.91 on Friday. The stock's 50 day simple moving average is $327.60 and its 200 day simple moving average is $304.83. Insulet Corporation has a twelve month low of $226.50 and a twelve month high of $353.50. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. The company has a market capitalization of $22.59 billion, a price-to-earnings ratio of 97.54, a PEG ratio of 2.68 and a beta of 1.40.

Insulet (NASDAQ:PODD - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The company had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. During the same quarter last year, the company posted $0.55 earnings per share. The company's revenue for the quarter was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, research analysts predict that Insulet Corporation will post 3.92 EPS for the current year.

Analyst Ratings Changes

PODD has been the topic of several recent analyst reports. Rothschild & Co Redburn upped their price target on Insulet from $350.00 to $370.00 and gave the company a "buy" rating in a research report on Friday, October 3rd. Piper Sandler upped their target price on Insulet from $320.00 to $360.00 and gave the company an "overweight" rating in a report on Tuesday, September 16th. Wall Street Zen raised shares of Insulet from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. The Goldman Sachs Group lowered their price objective on shares of Insulet from $399.00 to $375.00 and set a "buy" rating on the stock in a research report on Wednesday, October 1st. Finally, Wells Fargo & Company upped their price objective on shares of Insulet from $330.00 to $350.00 and gave the company an "overweight" rating in a research note on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $352.11.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.